Annual revenue rose from KRW 617.4 billion in 2022 to KRW 628.6 billion in 2023, up 1.8%, fell to KRW 597.6 billion in 2024, down 4.9%, and recovered to KRW 645.2 billion in 2025, up 8.0%.
Reports attributed the 2023 operating profit of KRW 20.2 billion to growth in health food sales from a wider overseas customer base and to cost structure improvements in health food and pharmaceuticals.
Operating profit fell to KRW 16.8 billion in 2024, down 17.1%, when the health food segment's operating profit dropped 52% to KRW 5.7 billion. Operating profit rose to KRW 27 billion in 2025, up 60.7%, and the operating margin reached 4.2%, up from 0.6% in 2022.
Net profit attributable to owners moved from a loss of KRW 6.53 billion in 2022 to a profit of KRW 9.06 billion in 2023, then to KRW 16.5 billion in 2024 and KRW 29.2 billion in 2025, up 77.5%.
Net profit including non-controlling interests was KRW 18.7 billion in 2025, below the figure attributable to owners, which suggests a loss in non-controlling interests drove the gap. Operating cash flow was KRW 35.2 billion in 2025, up from KRW 23.8 billion in 2024.
On a quarterly basis, operating profit was KRW 3.18 billion in Q3 2025 and jumped to KRW 7.36 billion in Q4 2025, up 131.4%. Q1 2026 revenue reached KRW 205.2 billion and operating profit peaked at KRW 16.4 billion, up 122.9% from the prior quarter.
Q2 2026 revenue rose to KRW 239 billion, but operating profit was flat at KRW 16.3 billion, down 0.9%. Q3 2026 revenue was KRW 241 billion, while operating profit fell to KRW 11.8 billion, down 27.5% from the prior quarter.
Net profit attributable to owners was KRW 29.3 billion in Q2 2026 and KRW 15.1 billion in Q3 2026, so quarterly owner profit did not track operating profit. Net profit attributable to owners totaled KRW 80.8 billion over the last four quarters, from Q4 2025 to Q3 2026. Total liabilities were KRW 710.7 billion at the end of 2025, against total equity of KRW 295.7 billion.